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*Introduction*: Significant advances in antiretroviral therapy have transformed HIV into a chronic manageable disease, and millions of women living with HIV now have the opportunity to reconsider their reproductive choices, be it contraception or pregnancy planning. Hormonal contraceptives are metabolized by cytochrome p450 isoenzymes and sulfate and glucuronide conjugation in the liver. Many antiretrovirals have inducing or inhibiting effects on the cytochrome p450 system. As such, the pharmacokinetics of hormonal contraceptives can be affected by antiretroviral therapy with potential for significant clinical impact.

*Areas Covered*: This article presents the pharmacology and metabolism of selected antiretrovirals and hormonal contraceptives, and highlights the potential interactions between these two classes of drugs. Furthermore, the authors present the pharmacokinetic evidence of interactions from available clinical trials, product monographs, and international conference abstracts.

*Expert Opinion*: Drugs most likely to interact with combined oral contraceptives; transdermal and implant contraceptives include protease inhibitors, the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine, and cobicistat-boosted elvitegravir. There do not appear to be significant pharmacokinetic interactions with depo-medroxyprogesterone or intrauterine systems and antiretrovirals, although further study is needed. Clinicians working with HIV-positive women need to know the significance of these interactions in order to properly counsel patients and prevent unplanned pregnancies.

Contraception for the HIV-positive Woman: A review of interactions between hormonal contraception and antiretroviral therapy

Robinson JA, Jamshidi R, Burke AE. Contraception for the HIV-positive woman: A review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol 2012;2012:890160.

*Background*: Preventing unintended pregnancy in HIV-positive women can significantly reduce maternal-to-child HIV transmission as well as improve the woman\'s overall health. Hormonal contraceptives (HCs) are safe and effective means to avoid unintended pregnancy, but there is concern that co-administration of antiretroviral drugs (ARVs) may alter contraceptive efficacy.

*Materials and Methods*: We performed a literature search of PubMed and Ovid databases of articles published between January 1980 and February 2012 to identify English-language reports of drug-drug interactions between HCs and ARVs. We also reviewed the FDA prescribing information of contraceptive hormone preparations and antiretrovirals for additional data and recommendations.

*Results*: Twenty peer-reviewed publications and 42 pharmaceutical package labels were reviewed. Several studies of combined oral contraceptive pills (COCs) identified decreased serum estrogen and progestin levels when co-administered with certain ARVs. The contraceptive efficacy of injectable depot medroxyprogesterone acetate (DMPA) and the levonorgestrel intrauterine system (LNG-IUS) were largely unaffected by ARVs while data on the contraceptive patch, ring, and implant were lacking.

*Conclusions*: HIV-positive women should be offered a full range of HC options, with conscientious counseling about possibly reduced efficacy of COCs and the contraceptive implant when taken with ARVs. DMPA and the LNG-IUS maintain their contraceptive efficacy when taken with ARVs.

Effect of injectable contraceptive use on response to antiretroviral therapy among women in Rakai, Uganda

Polis CB, Nakigozi G, Ssempijja V, Makumbi FE, Boaz I, Reynolds SJ, *et al.* Effect of injectable contraceptive use on response to antiretroviral therapy among women in Rakai, Uganda. Contraception 2012;86:725-30.

*Background*: There is limited evidence on the effect of injectable contraception on response to antiretroviral therapy (ART).

*Design*: Using modified Poisson regression, we assessed data from 418 female Ugandan ART initiators to examine the effect of injectable contraceptive use on a composite virologic failure outcome (defined as failure to achieve virologic suppression, switch to second-line therapy, or death within 12 months of ART initiation) and also assessed ART adherence.

*Results*: About 12% of women reported using injectable contraceptives at ART initiation, and their composite virologic failure rates 12 months later were similar to women not using injectable contraceptives at ART initiation (11% vs. 12%, *P* = 0.99). Multivariable Poisson regression suggested no significant differences in virologic failure by injectable contraceptive use at baseline (prevalence risk ratio: 0.85, *P* = 0.71), but the power was limited. Adherence to ART increased with time since ART initiation and did not appear to differ between injectable contraceptive users and nonusers.

*Conclusions*: Consistent with current World Health Organization guidelines, our results suggest no deleterious effect of injectable contraceptive use on response to ART, but power was limited, injectable contraceptive use patterns over time were inconsistent and additional evidence is needed.

Contraception in the context of HIV/AIDS: A review

Agboghoroma CO. Contraception in the context of HIV/AIDS: A review. Afr J Reprod Health 2011;15:15-23.

Over 50% of the 33.3 million HIV-positive persons are women within the reproductive age group. With increasing availability and use of highly active antiretroviral therapy (HAART), the prognosis, life expectancy, and quality-of-life of infected persons has improved. HIV-positive women, like their uninfected counterparts, may desire to plan pregnancies, limit their families, or avoid pregnancy. The effective use of contraception by HIV-positive clients can contribute significantly to a reduction in both sexual and vertical transmission of the virus. HIV-positive clients can use most of the available contraception methods including barrier, hormonal, intrauterine devices, and sterilization. However, some antiretroviral drugs interact with hormonal contraceptives with potentials for reduction in efficacy. Dual protection with concomitant use of a more effective contraceptive method and male or female condom to prevent HIV and sexually transmitted infections is the standard. It is necessary to make provision for contraceptive service as part of comprehensive care for the HIV-positive client.

Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives

El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13:123-32.

*Objectives*: The objective was to review available information on pharmacokinetic effects of HIV antiretrovirals on hormonal contraceptives.

*Methods*: A PubMed search was conducted from 1964 to 2006 using each antiretroviral generic name and the keywords contraceptive contraception and progestin. Abstracts from the annual Conference on Retroviruses and Opportunistic Infections and International AIDS Society Conferences from 1998 to 2006 as well as package product inserts were reviewed for completeness, ethinyl estradiol, estrogen.

*Results*: Antiretroviral regimens containing protease inhibitors and nonnucleoside reverse transcriptase inhibitors may decrease the area under the curve levels of steroids released by hormonal contraceptives. Some antiretroviral-hormonal contraceptive pairs do not decrease steroid hormone levels.

*Conclusion*: Pharmacokinetic interactions of antiretrovirals on hormonal contraceptives are specific to the type of antiretroviral and hormonal contraceptive being utilized. HIV-positive women may be counseled to use dual methods of hormonal and barrier contraception to prevent pregnancy with maximal efficacy as well as to reduce the possibility of HIV transmission. Oral contraceptives might be administered with nonritonavir boosted atazanavir or nonritonavir boosted indinavir without a loss of contraceptive efficacy. Depot medroxyprogesterone acetate may be safe to administer with efavirenz, nevirapine, and nelfinavir. However, further studies are needed to determine the clinical relevance of the interactions between hormonal contraceptives and antiretrovirals and to explore potential dose adjustments to improve contraceptive efficacy.

Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics, and pharmacodynamics

Thurman AR, Anderson S, Doncel GF. Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol 2014;71:523-30.

Among women, human immunodeficiency virus type 1 (HIV-1) infection is most prevalent in those of reproductive age. These women are also at risk of unintended or mistimed pregnancies. Hormonal contraceptives (HCs) are one of the most commonly used methods of family planning worldwide. Therefore, concurrent use of HC among women on antiretroviral medications (ARVs) is increasingly common. ARVs are being investigated and have been approved for preexposure prophylaxis and, therefore, drug-drug interactions must also be considered in HIV-1-negative women who want to prevent both unintended pregnancy and HIV-1 infection. This article will review four main interactions: (i) The effect of HCs on ARV pharmacokinetics (PK) and pharmacodynamics (PD) during therapy, (ii) the effect of ARVs on HC PK and PD, (iii) the role of drug transporters on drug-drug interactions, and (iv) ongoing research into the effect of HCs on preexposure prophylaxis PK and PD.

Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness

Nanda K, Delany-Moretlwe S, Dubé K, Lendvay A, Kwok C, Molife L, *et al.* Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. AIDS 2013;27 Suppl 1:S17-25.

*Objective*: The objective was to evaluate the effect of nevirapine-containing antiretroviral therapy (ART) on combined oral contraceptive (COC) effectiveness.

*Design*: Nonrandomized prospective clinical trial.

*Methods*: We enrolled HIV-infected women aged 18-35 years in South Africa and Uganda, who had regular menses, were sexually active and had no medical contraindications to COC use. We enrolled 196 women taking nevirapine-containing ART and 206 women not yet eligible for ART as a control group. We treated all participants with low-dose COCs. Our main outcomes were ovulation and pregnancy rates. We estimated ovulation in the first two cycles using weekly serum progesterone and tested for pregnancy monthly for 24 weeks.

*Results*: The median age of participants was 29, and their median CD4 cell count was 486. In the ART group, 43 of 168 (26%) ovulated in cycle 1, 30 of 163 (18%) in cycle 2, and 18 of 163 (11%) in both cycles. In the non-ART group, 26 of 168 (16%) ovulated in cycle 1, 31 of 165 (19%) in cycle 2, and 20 of 165 (12%) in both cycles. We found no significant difference in ovulation rates between groups: Unadjusted odds ratio 1.36 (95% confidence interval 0.85--2.18). Pregnancy rates also did not differ: 10.0/100-women-years in the ART group and 10.1/100-women-years in the non-ART group. Self-reported COC adherence, condom use, vaginal bleeding, and adverse events were similar. Five serious adverse events were reported, all in the non-ART group.

*Conclusion*: ART use did not affect the risk of ovulation or pregnancy in women taking COCs, suggesting that nevirapine-containing ART does not interfere with COC contraceptive effectiveness.

Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when co-administered with combined oral contraceptives

Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, *et al.* Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. J Acquir Immune Defic Syndr 2013;62:534-9.

*Background*: Effective contraception has been widely promoted for HIV-positive women. However, there are limited data on the interactions between combined hormonal contraceptives and nonnucleoside reverse transcriptase inhibitors.

*Methods*: This study assessed the steady-state contraceptive effectiveness and safety of combined oral contraceptive (COC) containing 0.150 mg desogestrel/0.030 mg ethinyl estradiol with either nevirapine (NVP) or efavirenz (EFV) in 34 HIV-positive women. The targeted level for contraceptive effectiveness was endogenous progesterone level \<3.0 ng/mL. We measured NVP/EFV plasma concentrations 12 h after administration (C12) with and without COC. The desired therapeutic levels were \>3.1 mg/L for NVP and 1.0--4.0 mg/L for EFV, respectively.

*Results*: All 18 subjects in the NVP group had serum progesterone \<1.0 ng/mL. Four of 16 subjects (25%) in the EFV group had serum progesterone \>1.0 ng/mL, including 3 subjects with \>3.0 ng/mL (might indicate ovulation). The difference in progesterone levels between the 2 groups was statistically significant (*P* = 0.04). The median C12 of NVP increased insignificantly by 17% with COC; the median C12 of EFV decreased significantly (*P* = 0.02) by 22%. In 3 of 16 subjects (19%) in the EFV group, C12 of EFV dropped below 1.0 mg/L.

*Conclusions*: In contrast to NVP, co-administrating desogestrel/ethinyl estradiol containing COC with EFV was associated with unfavorable progesterone and antiretroviral levels. Our results suggest that NVP may be superior to EFV when used with COC in HIV-positive women.
